Investment Thesis
Arbutus Biopharma is in severe financial distress with collapsing revenues (-66% YoY), massive operating losses (-$32.9M), and negative free cash flow of -$35M, indicating the company is burning cash at an unsustainable rate. While the company maintains adequate liquidity with $22.4M cash and zero debt, current burn rate suggests less than 8 months of runway without significant operational turnaround or financing. The business fundamentals show a company in crisis requiring urgent revenue recovery or strategic capital infusion.
ABUS Strengths
- Strong liquidity position with $22.4M cash and no debt
- Low financial leverage with zero long-term debt provides flexibility
- Current ratio of 18.80x demonstrates short-term solvency
ABUS Risks
- Revenue collapsed 66% YoY indicating severe operational challenges
- Negative free cash flow of -$35M at burn rate exceeding remaining cash runway
- Operating losses of -$252% margin with no path to profitability demonstrated
- Limited financial runway of approximately 6-8 months at current burn rate
- Pharmaceutical sector requires successful clinical development and regulatory approvals
Key Metrics to Watch
- Quarterly revenue trend and stabilization signals
- Monthly cash burn rate and runway projections
- Operating expense reductions and cost control measures
- Progress on clinical pipeline and regulatory milestones
- Financing activities and capital infusion announcements
ABUS Financial Metrics
Revenue
$13.0M
Net Income
$-29.7M
EPS (Diluted)
$-0.16
Free Cash Flow
$-35.0M
Total Assets
$97.7M
Cash Position
$22.4M
ABUS Profitability Ratios
Gross Margin
N/A
Operating Margin
-252.2%
Net Margin
-228.2%
ROE
-38.4%
ROA
-30.4%
FCF Margin
-268.2%
ABUS Balance Sheet & Liquidity
Current Ratio
18.80x
Quick Ratio
18.80x
Debt/Equity
0.00x
Debt/Assets
20.8%
Interest Coverage
-421.41x
Long-term Debt
$0.0
Disclaimer: This analysis is generated by Claude AI based on publicly available SEC EDGAR filings.
It does not include stock price data and should not be considered financial advice.
All fundamental data is sourced from SEC public domain filings.
Always conduct your own research and consult with a qualified financial advisor before making investment decisions.
Data Source: SEC EDGAR |
Analysis Date: Mar 19, 2026 |
Data as of: 2025-09-30 |
Powered by Claude AI